Author

Anushka Ojha

Stony Brook UniversityORCID 0009-0008-7220-4201Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Amartya PaliD· 3 shared Jingfang G JuiD· 3 shared Iwao OjimaiD· 2 shared Lei Chen· 2 shared Hersh BendaleiD· 1 shared Hersh Bendale· 1 shared John G YueniD· 1 shared Max Chao· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Amartya PalORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 10, 2026

Developing a Multimodal miR-15a Mimic to Overcome Gemcitabine and RAS(ON) Inhibitor Daraxonrasib Resistance in Pancreatic Ductal Adenocarcinoma

Amartya Pal, Anushka Ojha, John G Yuen…·Jingfang G Ju

This paper develops a multimodal miR-15a-based therapeutic that overcomes resistance to gemcitabine and daraxonrasib in PDAC by combining gene regulation and nucleotide metabolism disruption, showing potent antitumor effects in vitro and in vivo.

DOI 10.64898/2026.11.07.765071

humanproteomics

𝕏 PostBluesky

Cancer BiologyJournal of Experimental & Clinical Cancer ResearchPeer-reviewedOct 27, 2026

Development of gemcitabine-modified miR-15a as a novel, multimodal treatment strategy to overcome 5-FU and oxaliplatin resistance in colorectal cancer

Anushka Ojha, A.S. Pal, Max Chao…·Jingfang Ju

This paper develops Gem-miR-15a, a gemcitabine-modified microRNA, which overcomes 5-FU and oxaliplatin resistance in colorectal cancer with high potency and low toxicity.

DOI 10.1186/s13046-026-03865-6

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 22, 2026

Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

A.S. Pal, Anushka Ojha, Hersh Bendale…·Jingfang Ju

This paper develops a multimodal miR-15a mimic to overcome PARP inhibitor resistance in ovarian cancer, showing synergy with olaparib and antitumor efficacy.

DOI 10.64898/2026.04.20.719456

humanexperimental assay

𝕏 PostBluesky